Loading…
Employees: 2,574
Size medmix (MEDX.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $537M, the 136th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 10.62 on 6 Nov 2026.
Performance Over six months the shares gained 24.2%, against -13.5% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue fell 6.6% over the last twelve months (peer median +5.8%); the operating margin is 6.3% (peer median 2.1%).
Valuation It trades at 24.4× forward earnings against a peer median of 25.2× (4th cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 437M | CHF 448M | CHF 484M | CHF 487M | CHF 477M |
| Revenue growth | — | -7% | -1% | +2% | — |
| Gross profit | CHF 160M | CHF 162M | CHF 160M | CHF 158M | CHF 175M |
| EBITDA | CHF 78.4M | CHF 79.7M | CHF 74.3M | CHF 68.4M | CHF 95.8M |
| Net income | CHF 100,000 | CHF 6.40M | -CHF 7.40M | CHF 300,000 | CHF 11.6M |
| Free cash flow | CHF 31.7M | CHF 33.3M | CHF 48.1M | CHF 9.70M | CHF 11.2M |
| Capital expenditure | CHF 32.0M | CHF 41.1M | CHF 48.5M | CHF 52.9M | CHF 38.6M |
| Total debt | n/a | CHF 330M | CHF 323M | CHF 350M | CHF 474M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDX.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.8% | -4.3% | 5th highest of 20 |
| 6-month return | +24.2% | -13.5% | 5th highest of 20 |
| Distance from 52-week high | -14.1% | -37.3% | 3rd highest of 20 |
| Revenue growth (TTM) | -6.6% | +5.8% | 6th lowest of 20 |
| Operating margin | 6.3% | 2.1% | 7th highest of 20 |
| Forward P/E | 24.4× | 25.2× | 4th cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 7.8% | 3rd least demanding of 10 |
| Growth delivered (Del g) | +5.0% | +4.2% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +0.0 pp | +5.1 pp | 4th least demanding of 10 |
| ROIC minus cost of capital | -1.6 pp | -6.1 pp | 8th highest of 17 |
| EV / EBITDA | 8.3× | n/a | — |
| Net debt / EBITDA | 2.6× | -7.8× | most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 24.4× | 5.0% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 28.2× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 25.2× | 6.3% | +24.4% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 7.4× | -3.9% | -4.3% |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |